General Information of Drug (ID: DMMOWT9)

Drug Name
GSK3640254 Drug Info
Synonyms GSK'254
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Phase 2 [1]
Cross-matching ID
PubChem CID
118435805
TTD Drug ID
DMMOWT9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GSK2838232 DMCIGRW Human immunodeficiency virus-1 infection 1C62 Phase 2 [3]
BMS-955176 DMMEAGO Human immunodeficiency virus-1 infection 1C62 Phase 2 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Maturation (HIV Mat) TT5TOX7 NOUNIPROTAC Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03784079) A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults. U.S. National Institutes of Health.
2 Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor. Pharmacol Res Perspect. 2020 Dec;8(6):e00671.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037762)
4 Clinical pipeline report, company report or official report of Bristol-Myers Squibb.